Memorial Sloan Kettering Cancer Center shared on X:
“A new class of drugs known as menin inhibitors could stop the most lethal form of acute myeloid leukemia.
Research a decade ago paved the way for MSK hematologic oncologist Dr. Eytan Stein to lead a groundbreaking clinical trial for AML patients. Read more.”
Source: Memorial Sloan Kettering Cancer Center/X